The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
Euthansol-D (Canada)This page contains information on Euthansol-D for veterinary use.
The information provided typically includes the following:
- Euthansol-D Indications
- Warnings and cautions for Euthansol-D
- Direction and dosage information for Euthansol-D
Euthansol-DThis treatment applies to the following species:
Pentobarbital sodium and Phenytoin sodium Injection
Non-Sterile Euthanasia agent
VETERINARY USE ONLY
EUTHANSOL-D is a non-sterile injectable solution containing Pentobarbital sodium and Phenytoin sodium as the active ingredients. Rhodamine B, a bluish-red fluorescent dye, is included in the formulation to help distinguish this product from parenteral drugs intended for therapeutic use. Although the solution is not sterile, benzyl alcohol, a bacteriostatic, is included to retard the growth of microorganisms.
Each mL contains:
390 mg Pentobarbital sodium USP and 50 mg Phenytoin sodium USP.
Preservatives: 2% v/v benzyl alcohol.
For humane, painless and rapid euthanasia of dogs and cats.
Dosage and Administration
Tranquilization is recommended prior to administration, especially in agitated or nervous animals.
Dosage: Dogs and Cats: 1 mL for each 4.5 kg (10 pounds) of body weight.
Administration: The calculated dose should be given in a single bolus injection into a large peripheral vein through an intravenous (IV) catheter, to avoid local venous irritation due to the alkalinity of the solution. Prior to the administration, the patency of the IV catheter should be tested with a flush of sterile saline.
Intravenous injection is preferred. The intra-cardiac route should be used only when intravenous injection is impractical, as in a very small animal, or in an animal with impaired vascular functions. Intra-cardiac injection is only appropriate in unconscious or anesthetized animals.
For intravenous injection, a needle of sufficient gauge to ensure intravenous placement of the entire dose should be used. The use of a Luer-lock syringe is recommended to prevent accidental exposure due to needle/syringe separation.
Contra-Indications: Do not use for therapeutic purposes.
● The recommended dosage should be followed and overdosing avoided.
● Euthanasia may sometimes be delayed in animals with severe cardiac or circulatory deficiencies. This may be explained by the impaired movement of the drug to its site of action.
● When restraint may cause pain, injury, or anxiety, or danger to the person making the injection, prior use of analgesic, tranquilizing and/or immobilizing drugs may be necessary.
● An occasional animal may elicit reflex responses manifested by motor movement; however, an unconscious animal does not experience pain, because the cerebral cortex is not functioning.
● This product is toxic to wildlife. Birds and mammals feeding on treated animals may be killed. Euthanized animals must be properly disposed of by deep burial, incineration, or other method in compliance with province and local laws to prevent consumption of carcass material by scavenging wildlife.
KEEP OUT OF REACH OF CHILDREN.
Do not use in animals intended for food.
Caution should be exercised to avoid contact of the drug with open wounds or accidental self-inflicted injections. In case of eye contact, flush eyes with water and seek medical attention.
Although all adverse reactions are not reported, the following information is based on voluntary post-approval drug experience reporting. It is generally recognized that this results in significant under-reporting. The adverse events listed here reflect reporting and not necessarily causality. The following adverse events were reported very rarely:
- Injection site pain (manifested by signs of vocalization, agitation and /or excitation)
- Lack of efficacy (manifested by a delayed onset of death)
EUTHANSOL-D contains two active ingredients which are chemically compatible but pharmacologically different. Euthanasia is due to cerebral death in conjunction with respiratory arrest and circulatory collapse. Cerebral death occurs prior to cessation of cardiac activity.
Mode of Action: The sequence of events leading to humane, painless and rapid euthanasia following intravenous injection of EUTHANSOL-D is similar to that following intravenous injection of Pentobarbital sodium or other barbituric acid derivatives. Within seconds, unconsciousness is induced with simultaneous collapse of the animal. This stage rapidly progresses to deep anesthesia with concomitant reduction in the blood pressure. A few seconds later, breathing stops, due to depression of the medullary respiratory centre; encephalographic activity becomes isoelectric, indicating cerebral death, and then cardiac activity ceases.
Phenytoin sodium exerts its effect during the deep anesthesia stage caused by the Pentobarbital sodium. Due to its cardiotoxic properties, Phenytoin sodium hastens the cessation of electrical activity in the heart.
Store between 15° and 25°C.
EUTHANSOL-D is available in 100 mL multi-dose glass vials.
Intervet Canada Corp., Subsidiary of Merck & Co., Inc., 16750, route Transcanadienne, Kirkland, QC H9H 4M7
1 866 683-7838
® Intervet Canada Corp.
Version: February 14, 2018
Intervet Canada Corp.
16750 ROUTE TRANSCANADIENNE, KIRKLAND, QC, H9H 4M7
|Fax:||Toll-free 888-498-4444; local 514-428-7014|
|Every effort has been made to ensure the accuracy of the Euthansol-D information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2020 Animalytix LLC. Updated: 2020-10-21